Introduction
Semaglutide’s introduction marks a pivotal moment in the fight against obesity, particularly for those navigating the challenges of weight management during perimenopause and menopause. Many individuals struggle to find effective weight loss solutions during critical transitions like these. This article explores ten key milestones in semaglutide’s development and approval, highlighting its impact on treatment options and the ongoing discussion about sustainable health management strategies. Understanding semaglutide’s development timeline may illuminate new pathways for addressing obesity and enhancing overall health outcomes.
Tyde Wellness: Pioneering Personalized GLP-1 Weight Loss Solutions
Managing body composition during perimenopause and menopause can be challenging for many women, but Tyde Wellness offers tailored solutions to address these unique needs. Utilizing GLP-1 medications, including specific agents, Tyde Wellness creates personalized programs that specifically address body composition challenges faced by women in this stage of life. By integrating GLP-1 medications with personalized nutrition and coaching, Tyde Wellness enhances the effectiveness of semaglutide while promoting sustainable lifestyle changes that help clients reach their goals without restrictive diets.
Tyde Wellness adopts a holistic approach that includes:
- Hormone balance through safe GLP-1 and HRT options
- Custom fitness plans designed to rebuild strength and enhance metabolism
- Smart nutrition guides that help curb cravings while supporting bone and cardiovascular well-being
Research from clinical trials indicates that women using GLP-1 medications can lose an average of 10.88% of their initial body mass, which underscores the potential for significant health improvements. Furthermore, case studies exploring psychological challenges after shedding pounds indicate that patients frequently experience improved mood and energy levels alongside this change, further highlighting the diverse advantages of these programs.
By combining medical guidance with personalized care, Tyde Wellness ensures clients receive effective support tailored to their needs, establishing it as a leader in the evolving landscape of management solutions. By prioritizing personalized care and medical expertise, Tyde Wellness empowers women to achieve lasting health improvements and enhanced well-being.
FDA Approval of Semaglutide: A Turning Point in Weight Loss Treatments
In June 2021, the FDA’s approval of Wegovy marked a pivotal advancement in obesity treatment, providing a new avenue for individuals struggling with weight management. Clinical trials demonstrated that participants using the 2.4 mg dosage experienced an average weight reduction of 16% over 72 weeks, while those on the higher 7.2 mg dosage saw an impressive 19% reduction. This new medication is changing the way we think about body transformation, offering a scientifically supported option for those who have faced challenges with conventional diet and exercise approaches.
Furthermore, in the STEP UP trial, 31% of participants achieved at least a 25% reduction in body mass, highlighting the medication’s effectiveness. At Tyde Wellness, we employ GLP-1 medications approved by the FDA, including tirzepatide, as part of our Transform program, which provides customized doctor-prescribed solutions for sustainable health management.
The approval of semaglutide, which prompts the question of when did semaglutide come out, not only signifies progress in weight management but also underscores the urgent need for comprehensive strategies to combat obesity’s broader health implications.
Clinical Trials of Semaglutide: Validating Weight Loss Efficacy
The STEP clinical trials have demonstrated that semaglutide can significantly aid in weight loss and improve metabolic health. Participants in these trials experienced an impressive average loss of 15% over 68 weeks, significantly outperforming those in the placebo group. Furthermore, the STEP trials uncovered substantial improvements in key metabolic wellness markers, including blood sugar levels and cardiovascular risk factors. These results demonstrate that semaglutide effectively supports weight management and improves overall health, making it a vital choice for those seeking sustainable health improvements.
Tyde Wellness offers customized programs, such as the Transform program, which employs semaglutide to assist clients in reaching their goals for reducing body mass. Real-world results from clients further demonstrate this effect: many have reported significant reductions in body mass and improved well-being.
One client shared, ‘I’ve lost nearly 20 pounds in just two months! I feel fantastic and so much healthier.’ Another noted, ‘Weight is falling off me with no side effects.’ These testimonials show how Tyde Wellness helps clients achieve significant health improvements through personalized management.
Launch of Semaglutide for Obesity Management: Expanding Treatment Options
Many individuals struggle with traditional weight loss methods, often facing plateaus and frustration. The introduction of a new medication for obesity management has transformed treatment alternatives for those encountering challenges in shedding pounds. Unlike conventional medications, this treatment mimics the GLP-1 hormone, which plays a crucial role in enhancing fullness and reducing hunger. This innovative approach is increasingly recognized by healthcare providers, including those at Tyde Wellness, who prioritize evidence-based solutions tailored to their clients’ specific needs.
In clinical studies, nearly a third of participants using the medication achieved a remarkable 20% reduction in body mass, while half lost 15% after 68 weeks. This underscores its effectiveness, especially when combined with lifestyle changes. As a result, this medication offers a new pathway for those who have struggled to achieve their weight loss goals. This medication not only provides a new option but also fosters a renewed sense of hope for sustainable health management.
Impact of Semaglutide on Obesity Trends: A Public Health Perspective
The introduction of this medication could fundamentally alter the trajectory of obesity trends in the U.S. Research indicates that effective body composition management can significantly lower obesity rates, which is crucial given the concerning rise in obesity-related health issues. Currently, around 6% of adults in the U.S. are prescribed anti-obesity medications, with a prominent option emerging due to its notable reduction in body mass and cardiovascular benefits.
Experts in public health emphasize that this medication helps people achieve their weight loss goals while contributing to broader efforts to mitigate the impact of obesity and its related health conditions. For instance, the rapid uptake of Wegovy, with over three million prescriptions filled within just five months of its launch, underscores its acceptance as a viable treatment option. This growing demand reflects a shift in public perception, recognizing obesity as a chronic metabolic disease rather than merely a cosmetic issue.
For example, the Phase 3 results from Novo Nordisk’s REIMAGINE trials show the medication’s effectiveness in managing body composition and improving metabolic function among participants. These findings highlight the medication’s role in addressing the obesity epidemic, which affects millions of Americans and contributes to conditions like type 2 diabetes and heart disease.
Despite advancements in treatment, obesity continues to be a pressing issue in the U.S., underscoring the urgent need for effective interventions to combat obesity. By offering a medically guided strategy for reducing body mass, this treatment empowers individuals and aligns with public health objectives to decrease obesity rates and enhance overall well-being across communities. As S. Hayes shares, ‘Dr. Kelly took the time to explain everything clearly, ensuring I always knew what to expect at each step of the process. I’m excited to share that I’ve lost nearly 20 pounds in just two months! I feel fantastic and so much healthier.’ This testimonial illustrates how Tyde Wellness’s personalized GLP-1 programs, including the Transform, Balance, and Thrive programs, can lead to substantial reductions in body mass and improved health, highlighting the effectiveness of their approach. This underscores the importance of personalized treatment approaches in the fight against obesity.
Evolution of GLP-1 Medications: The Journey to Semaglutide
The journey of GLP-1 medications showcases the intricate process of developing effective treatments for appetite regulation and glucose metabolism. The first GLP-1 receptor agonist, liraglutide, received FDA approval in 2010 for diabetes management, marking a pivotal moment in obesity treatment. When did semaglutide come out in 2017? The medication was introduced, marking a significant leap forward with its enhanced efficacy and the convenience of a once-weekly dosing schedule. This advancement is a testament to ongoing research and innovation in the field. Studies indicate that the medication can lead to an average reduction of 10-15% over a year, as supported by the NEJM STEP 1 and SURMOUNT-1 clinical trials. The development journey involved synthesizing hundreds of variations; despite numerous attempts, earlier versions of the medication did not achieve the desired efficacy. This collaborative effort among researchers highlights the commitment to improving treatment options for those struggling with body composition.
At Tyde Wellness, we harness the power of GLP-1 medications in our tailored programs to help you manage your body composition. Our programs feature:
- Personalized nutrition strategies
- Expert guidance from wellness coaches
- Optional peptide therapy options
They are crafted to promote sustainable body management, with competitive cash-pay options available for compounded GLP-1 medications when insurance coverage is not feasible. This endorsement signifies progress in drug development and highlights the potential of GLP-1 therapies to address broader health concerns, including obesity and its associated risks. They are now a key component of our holistic approach to sustainable management.
Semaglutide and Comorbidities: Addressing Health Beyond Weight Loss
Semaglutide offers a multifaceted approach to health, addressing not just weight loss but also critical comorbidities linked to obesity. Its benefits extend significantly to conditions like type 2 diabetes, hypertension, and cardiovascular disease. Clinical studies reveal that patients using this medication achieve substantial weight loss, with participants reporting an average body mass decrease of 15% after 68 weeks. Furthermore, they experience notable improvements in glycemic control and reductions in cardiovascular risk factors. For instance, the SUSTAIN-6 trial demonstrated a 26% reduction in major adverse cardiovascular events among patients with type 2 diabetes, highlighting the cardioprotective effects of the medication.
This approach is especially helpful for women facing unique health challenges during perimenopause and menopause. At Tyde Wellness, we offer personalized solutions to help reduce excess weight through our doctor-led GLP-1 therapy, empowering women to tackle hormonal-related challenges with safe alternatives. Additionally, we focus on reducing ‘Food Noise’ and enhancing ‘Metabolic Health,’ further improving the effectiveness of our programs. This medication also shows promise in alleviating symptoms of chronic ailments, making it a beneficial choice for individuals looking to improve their overall health while managing body composition effectively.
However, patients may face challenges such as gastrointestinal issues and the risk of pancreatitis. It’s crucial for patients to consult with a healthcare professional to discuss the appropriate dosing guidelines. This ensures that patients receive personalized care tailored to their specific health needs. Research shows that this therapy can lead to significant improvements in metabolic parameters, further supporting its role in addressing obesity-related health issues, particularly for women seeking sustainable weight loss solutions. Ultimately, understanding the full scope of Semaglutide’s effects can empower individuals to make informed decisions about their health journey.
Accessibility of Semaglutide: Economic Factors Influencing Adoption
Access to essential medications like Ozempic and Wegovy is increasingly challenging due to high costs and inconsistent insurance coverage. Many individuals face significant financial barriers when trying to access this essential medication. The typical out-of-pocket expenses for Ozempic injections average around $1,027.51, while Wegovy injections can reach approximately $1,349.02. These financial obstacles disproportionately affect women with health issues, underscoring the urgent need for policy changes to ensure fair access to treatment benefits.
While compounded versions of this medication may be more affordable, they lack FDA approval and could pose quality and safety risks. Tyde Wellness offers solutions for those facing insurance challenges, including:
- Compounded GLP-1 medications
- Comprehensive programs like the Transform program with FDA-approved GLP-1 medications
- The Balance program with micro-dosed weight loss medications
- The Thrive program focused on coaching and peptide therapies
Patient assistance programs, such as NovoCare and grants from the PAN Foundation, can help alleviate some financial burdens for those in need.
With the obesity crisis affecting about 42% of U.S. adults, addressing these economic inequalities is vital for ensuring everyone can access effective treatments. Start your journey to lasting health with Tyde Wellness-book your consultation today!
Future Directions for Semaglutide: Ongoing Research and Innovations
Research into this medication is rapidly evolving, revealing promising insights into its long-term effects and potential new uses. Current studies are looking into new oral formulations and different dosing schedules to improve how well patients stick to their treatment and the results they achieve. Significantly, the OASIS trials have shown remarkable reductions in body mass, with participants achieving an average of 15.1% loss after 68 weeks using oral medication, compared to just 2.4% in the placebo group.
Future studies are particularly concentrated on incorporating the medication into comprehensive management programs, especially for women undergoing hormonal changes during postpartum recovery and menopause. Women undergoing hormonal changes often face unique challenges that can complicate weight management. This approach not only addresses weight loss but also promotes overall health improvements for these women.
At Tyde Wellness, we also provide optional peptide therapy treatments alongside our Transform program with full-strength FDA-approved GLP-1 medications and the Balance program featuring micro-dosed medications for managing body composition. With these advancements, we could see semaglutide becoming even more effective in tackling obesity and its related health issues, raising the question of when did semaglutide come out.
Semaglutide’s Transformative Role in Weight Loss: A Comprehensive Overview
Semaglutide represents a significant advancement in weight management, offering a scientifically supported method for achieving sustainable body transformation. Its unique mechanism helps suppress appetite and regulate metabolism, leading to significant improvements in body composition. In clinical studies, participants utilizing the medication experienced substantial reductions in body mass, with half of the individuals in a trial involving 2,000 obese adults shedding 15% of their body mass after 68 weeks, and nearly a third achieving a 20% decrease.
The transformative impacts of the medication extend beyond fat reduction; it has also been shown to improve comorbidities linked to obesity, such as cardiovascular risk, regardless of blood sugar levels. This is especially important for women, who often face unique challenges in managing body composition during hormonal changes, such as postpartum recovery and menopause.
At Tyde Wellness, we focus on using a specific medication as part of our personalized transformation programs, including our Transform program, which features full-strength FDA-approved GLP-1 medications tailored to meet the distinct needs of women. Case studies demonstrate the effectiveness of the medication; for instance, in a multicenter clinical trial, participants receiving a higher dosage of the drug lost an average of 13.2% of their body mass over 72 weeks, significantly surpassing those on standard dosages. This highlights how customized dosing strategies can significantly enhance fat loss outcomes, leading to more effective weight management.
Expert opinions reinforce the value of this medication in obesity treatment. As research continues to advance, the role of semaglutide in managing body composition is expected to grow, providing hope and effective solutions for those pursuing lasting wellness improvements. With Tyde Wellness, you’re not just losing weight; you’re embarking on a journey toward a healthier, more empowered life.
Conclusion
Semaglutide represents a significant advancement in weight management, especially for women experiencing perimenopause and menopause. Tyde Wellness is leading the way in this exciting transformation, offering personalized GLP-1 medication programs that combine medical expertise with tailored nutrition and exercise plans. This comprehensive approach addresses weight loss while promoting lasting lifestyle changes, empowering clients to achieve their health goals without the burden of restrictive diets.
Throughout the article, we highlighted key milestones in the development and approval of semaglutide, showcasing its efficacy in clinical trials and its significant impact on obesity treatment. The FDA’s approval of Wegovy in June 2021 marked a pivotal moment, providing a scientifically supported option for individuals struggling with weight management. Results from various studies demonstrate that semaglutide can lead to substantial weight loss while also improving metabolic health and reducing the risk of obesity-related comorbidities. Tyde Wellness’s commitment to personalized care ensures that clients receive the support they need to navigate their unique health journeys effectively.
As obesity treatment evolves, accessible and effective solutions are more important than ever. Tyde Wellness not only offers innovative programs that incorporate semaglutide but also addresses the economic barriers that many individuals face in affording essential medications for weight management. By prioritizing compassionate, evidence-based care, Tyde Wellness empowers individuals to take charge of their health and well-being. By embracing this innovative approach, individuals can significantly enhance their quality of life and health outcomes.
Frequently Asked Questions
What solutions does Tyde Wellness offer for managing body composition during perimenopause and menopause?
Tyde Wellness offers tailored solutions utilizing GLP-1 medications, personalized nutrition, and coaching to address body composition challenges faced by women during perimenopause and menopause.
How does Tyde Wellness enhance the effectiveness of GLP-1 medications like semaglutide?
Tyde Wellness enhances the effectiveness of GLP-1 medications by integrating them with personalized nutrition and coaching, promoting sustainable lifestyle changes without restrictive diets.
What holistic approaches does Tyde Wellness incorporate in their programs?
Tyde Wellness incorporates hormone balance through safe GLP-1 and HRT options, custom fitness plans to rebuild strength and enhance metabolism, and smart nutrition guides to curb cravings while supporting bone and cardiovascular health.
What are the average weight loss results from using GLP-1 medications according to clinical trials?
Research indicates that women using GLP-1 medications can lose an average of 10.88% of their initial body mass, with significant health improvements reported.
What psychological benefits have been observed in patients after weight loss with GLP-1 medications?
Patients frequently experience improved mood and energy levels alongside weight loss, highlighting the diverse advantages of these programs.
What is the significance of the FDA’s approval of semaglutide in weight loss treatments?
The FDA’s approval of Wegovy in June 2021 marked a pivotal advancement in obesity treatment, providing a scientifically supported option for individuals struggling with weight management.
What were the results of clinical trials for semaglutide regarding weight reduction?
Clinical trials demonstrated that participants using the 2.4 mg dosage experienced an average weight reduction of 16% over 72 weeks, while those on the higher 7.2 mg dosage saw a 19% reduction.
How does Tyde Wellness utilize semaglutide in their programs?
Tyde Wellness employs FDA-approved GLP-1 medications, including semaglutide, as part of their Transform program, which provides customized doctor-prescribed solutions for sustainable health management.
What improvements in metabolic health have been observed in the STEP clinical trials for semaglutide?
The STEP clinical trials showed that participants experienced an average weight loss of 15% over 68 weeks and significant improvements in key metabolic wellness markers, including blood sugar levels and cardiovascular risk factors.
Can you provide examples of client testimonials regarding their experiences with Tyde Wellness?
Clients have reported significant results, such as one stating, “I’ve lost nearly 20 pounds in just two months! I feel fantastic and so much healthier,” and another noting, “Weight is falling off me with no side effects.
List of Sources
- Tyde Wellness: Pioneering Personalized GLP-1 Weight Loss Solutions
- GLP-1 Weight-Loss Drugs Comparably Effective for Patients Across Age, Race, and Starting Weight | Johns Hopkins Bloomberg School of Public Health (https://publichealth.jhu.edu/2026/glp-1-weight-loss-drugs-comparably-effective-for-patients-across-age-race-and-starting-weight)
- Are the New Weight Loss Drugs Too Good to Be True? (https://magazine.ucsf.edu/weight-loss-drugs-too-good-to-be-true)
- Telehealth Booms As Demand For GLP-1s Surges and Questions Mount About Safety, Oversight (https://infectiousdiseaseadvisor.com/news/telehealth-booms-as-demand-for-glp-1s-surges-and-questions-mount-about-safety-oversight)
- Thinking about GLP-1 for weight loss? Here’s what to know (https://bswhealth.com/blog/glp-1-for-weight-loss)
- Products – Data Briefs – Number 537 – July 2025 (https://cdc.gov/nchs/products/databriefs/db537.htm)
- FDA Approval of Semaglutide: A Turning Point in Weight Loss Treatments
- FDA Approves Higher Dose Injectable Semaglutide (https://jamanetwork.com/journals/jama/article-abstract/2847412)
- FDA Approves Novo Nordisk’s New Wegovy HD Injection, Delivering the Highest Weight Loss to Date for a Wegovy Injection (https://drugs.com/newdrugs/fda-approves-novo-nordisk-s-new-wegovy-hd-delivering-highest-weight-loss-date-wegovy-6749.html)
- FDA Approves Oral Semaglutide as First GLP-1 Pill for Weight Loss | AJMC (https://ajmc.com/view/fda-approves-oral-semaglutide-as-first-glp-1-pill-for-weight-loss)
- Novo Nordisk receives FDA approval for Wegovy™ to treat adults with obesity based on unprecedented efficacy for a prescription medicine in clinical trials (https://prnewswire.com/news-releases/novo-nordisk-receives-fda-approval-for-wegovy-to-treat-adults-with-obesity-based-on-unprecedented-efficacy-for-a-prescription-medicine-in-clinical-trials-301306246.html)
- Clinical Trials of Semaglutide: Validating Weight Loss Efficacy
- New weight loss pill beats oral Ozempic in major trial (https://sciencedaily.com/releases/2026/07/260707054111.htm)
- Novo Nordisk Announces Results From STEP 5 Trial for Semaglutide | Pharmacy Times (https://pharmacytimes.com/view/novo-nordisk-announces-results-from-step-5-trial-for-semaglutide)
- STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo | Applied Clinical Trials Online (https://appliedclinicaltrialsonline.com/view/step-up-trial-semaglutide-superior-weight-loss)
- Launch of Semaglutide for Obesity Management: Expanding Treatment Options
- Semaglutide, also known as Ozempic, for weight loss – what you need to know (https://uclahealth.org/news/article/semaglutide-weight-loss-what-you-need-know)
- Client Challenge (https://nature.com/articles/d41586-026-00228-1)
- Novo Nordisk presents four new analyses on oral semaglutide 25 mg (Wegovy® in a pill*) at ObesityWeek® 2025, including demonstrated reductions in cardiovascular risk factors (https://prnewswire.com/news-releases/novo-nordisk-presents-four-new-analyses-on-oral-semaglutide-25-mg-wegovy-in-a-pill-at-obesityweek-2025-including-demonstrated-reductions-in-cardiovascular-risk-factors-302605329.html)
- Oral semaglutide linked to significant weight loss as Novo Nordisk awaits FDA approval (https://cardiovascularbusiness.com/topics/clinical/heart-health/oral-semaglutide-linked-significant-weight-loss-novo-nordisk-awaits-fda-approval)
- Impact of Semaglutide on Obesity Trends: A Public Health Perspective
- Obesity treatment trends in 2026 and beyond – Drug Discovery World (DDW) (https://ddw-online.com/obesity-treatment-trends-in-2026-and-beyond-40289-202602)
- The Rise of Ozempic for Weight Loss Sparks Ethical Concerns (https://columbiapsychiatry.org/news/rise-ozempic-sparks-ethical-concerns)
- Americans keep poisoning themselves with semaglutide, other weight loss drugs (https://cardiovascularbusiness.com/topics/clinical/heart-health/americans-keep-poisoning-themselves-semaglutide-other-weight-loss-drugs)
- Products – Data Briefs – Number 508 – September 2024 (https://cdc.gov/nchs/products/databriefs/db508.htm)
- Novo Nordisk to present new data on Wegovy® across a wide range of cardiometabolic conditions at the American Diabetes Association’s 2026 Scientific Sessions (https://prnewswire.com/news-releases/novo-nordisk-to-present-new-data-on-wegovy-across-a-wide-range-of-cardiometabolic-conditions-at-the-american-diabetes-associations-2026-scientific-sessions-302793265.html)
- Evolution of GLP-1 Medications: The Journey to Semaglutide
- Client Challenge (https://nature.com/articles/d41586-026-00228-1)
- The story of semaglutide (https://novonordisk.com/disease-areas/obesity/the-story-of-semaglutide.html)
- Inside the GLP-1 Revolution (https://medschool.duke.edu/news/inside-glp-1-revolution)
- How GLP-1 Drugs Went From Lab Discovery to Weight-Loss Breakthroughs (https://news.cuanschutz.edu/news-stories/how-glp-1-drugs-went-from-lab-discovery-to-weight-loss-breakthroughs)
- What is next in the evolution of GLP-1-based therapies for diabetes and obesity? (https://mcgill.ca/oss/article/medical-health-and-nutrition/what-next-evolution-glp-1-based-therapies-diabetes-and-obesity)
- Semaglutide and Comorbidities: Addressing Health Beyond Weight Loss
- Semaglutide: Double-edged Sword with Risks and Benefits – PMC (https://pmc.ncbi.nlm.nih.gov/articles/PMC11790292)
- Who will benefit from new ‘game-changing’ weight-loss drug semaglutide? (https://uab.edu/news/research-innovation/who-will-benefit-from-new-game-changing-weight-loss-drug-semaglutide)
- SELECT trial demonstrates semaglutide benefits beyond reduction of cardiovascular events – ADA Meeting News (https://adameetingnews.org/select-trial-demonstrates-semaglutide-benefits-beyond-reduction-of-cardiovascular-events)
- Accessibility of Semaglutide: Economic Factors Influencing Adoption
- The Rise of Ozempic for Weight Loss Sparks Ethical Concerns (https://columbiapsychiatry.org/news/rise-ozempic-sparks-ethical-concerns)
- Medicare to cover GLP-1 drugs for weight loss starting July 1. Here’s what to know. (https://cbsnews.com/news/medicare-glp1-weight-loss-drug-coverage-july-1)
- How Much Does Semaglutide Cost? – Policy Lab (https://policylab.us/semaglutide/cost)
- Economic Impact of GLP-1 Drugs in Obesity Treatment – European Society of Medicine (https://esmed.org/economic-impact-of-glp-1-drugs-in-obesity-treatment)
- Semaglutide – Drug Usage Statistics, ClinCalc DrugStats Database (https://clincalc.com/Drugstats/Drugs/Semaglutide)
- Future Directions for Semaglutide: Ongoing Research and Innovations
- 5 Projected GLP-1 Trends in 2026 – GoodRx (https://goodrx.com/classes/glp-1-agonists/glp-1-trends?srsltid=AfmBOop5q4ZTL9J1de6ZNSs5JZWfg55gGr228Ie4v3nphAP2qHQlWtcV)
- Late Breaking Weight Loss Innovations: New Drug Therapies Shown to Offer Positive Outcomes for Obesity and Type 2 Diabetes Management (https://prnewswire.com/news-releases/late-breaking-weight-loss-innovations-new-drug-therapies-shown-to-offer-positive-outcomes-for-obesity-and-type-2-diabetes-management-301862607.html)
- Future Directions in the Medical Treatment of Obesity: A Narrative Review – Advances in Therapy (https://link.springer.com/article/10.1007/s12325-026-03576-6)
- GLP-1 agonist clinical pipeline 2026: drugs and Phase 2 | Drug Discovery News (https://drugdiscoverynews.com/glp-1-agonist-clinical-pipeline-2026-semaglutide-tirzepatide-and-what-s-in-phase-2-17286)
- Semaglutide’s Transformative Role in Weight Loss: A Comprehensive Overview
- SELECT trial demonstrates semaglutide benefits beyond reduction of cardiovascular events – ADA Meeting News (https://adameetingnews.org/select-trial-demonstrates-semaglutide-benefits-beyond-reduction-of-cardiovascular-events)
- Semaglutide, also known as Ozempic, for weight loss – what you need to know (https://uclahealth.org/news/article/semaglutide-weight-loss-what-you-need-know)
- Higher dose of semaglutide increases weight loss, metabolic benefits – UT Southwestern Medical Center (https://physicianresources.utswmed.org/news/higher-dose-of-semaglutide-increases-weight-loss-metabolic-benefits)
- Adults with obesity treated with semaglutide 2.4 mg achieved and maintained a significant amount of weight loss in a 68-week trial (https://prnewswire.com/news-releases/adults-with-obesity-treated-with-semaglutide-2-4-mg-achieved-and-maintained-a-significant-amount-of-weight-loss-in-a-68-week-trial-301254177.html)
- New GLP-1 Drug Promotes Weight Loss in Obesity – News Center (https://news.feinberg.northwestern.edu/2026/06/24/new-glp-1-drug-promotes-weight-loss-in-obesity)
